Brain Tumor Related News!
Fundraisers For Brain Tumor Research!
Brain Tumor Conferences / Events
New Clinical Trials
Noteworthy Treatments Explanation of the new high tech treatments!
Conferences / Events
- No events scheduled. Please check back soon!
Brain Tumor News!
Note: The comments under each article title are the opinion of our president, Al Musella, DPM, and do not reflect official policy of the Musella Foundation!
Displaying Stories 1 to 20 of 6,392
07/10/18 Brain Tumor Webinar Series continues...
These events allow you to ask the experts any questions about brain tumor treatments.
Dr Rahman is the co-principal investigator for a promising vaccine clinical trial https://clinicaltrials.gov/ct2/show/NCT02465268 She will tell us the theory behind the vaccine and why she thinks it will help, as well as the results of an earlier trial.. This is a simple shot in the skin - not into the brain.
Dr Schulder is the director of the Brain Tumor Center at Northwell Health's Neuroscience Institute and they recently acquired the new version of the Gamma Knife. Dr. Schulder is past president of the American Society for Stereotactic and Functional Neurosurgery and is vice president of the World Society for Stereotactic and Functional Neurosurgery. He is one of the rare neurosurgeons who can and does treat brain tumors both with surgery and / or radiation.
06/30/18 Returning to work after multimodal treatment in glioblastoma patients
This should be a key endpoint for clinical trials for glioblastomas. In this study, only 18% of the patients went back to work after surgery, radiation and Temodar. Out of these who did go back to work, most were not able to resume full time work. Only about 8 out of the 125 patients were able to return to work full time. Some of the new experimental treatments such as DCVAX and Tocagen not only had some long term survivors, but had people working full time in high level jobs 5+ years after diagnosis. That is really what we want to see, even more than merely "surviving".
06/20/18 Dr. Souweidane’s Phase 1 Trial Findings Published in Lancet Oncology
This is the first proof that convection enhanced delivery into the brain of a kid with DIPG is safe. There is no talk about the effectiveness of the treatment - this is just the first step - to show it is possible. Next step is to try to see which drugs are best.
06/17/18 Pinning Down Patient Comfort With Gamma Knife Icon
This new version of the gamma knife doesn't require a frame screwed into the head any more!
We will be having a webinar with Dr Schulder in a few weeks to discuss this new version of the gamma knife!
06/02/18 Returning to work after multimodal treatment in glioblastoma patients.
Returning to work after multimodal treatment in glioblastoma patients. This is one of the most important outcome of brain tumor treatments. It should be considered an important primary endpoint for clinical trials: what % of patients are able to work full time at the level of their previous job at 1,2,3 year point? What % of patients can work at least part time at any job at 1,2,3 years. This is important because for the first time, we are seeing long term survivors of GBMs who can actually work full time at high level jobs, many years down the line. Even if a treatment only improves median survival by a small amount, but allows those who do survive to engage in meaningful work - that is a breakthrough. For example, many years ago there were reports of a high % of long term survivors with intense radiation. However, it caused so much damage that most survivors were bedridden for the rest of their lives. More recently, with DC-Vax, ICT-107, Toca 511 / Toca FC, and others, we see some long term survivors who are functioning at the highest level - executive jobs, having families, driving and enjoying life. That is what we strive for. So it should be a formal endpoint!
Displaying Stories 1 to 20 of 6392